PTPN22 and neoplasm: ,108,110 Thus, systemic administration of a PTPN22 selective inhibitor, L-1, reduced syngeneic tumor growth in Ptpn22+/+, but not Ptpn22-/-, mice and synergized with PD-1 blockade to mediate tumor clearance.108